An update on aspirin in the primary prevention of cardiovascular disease
about
A comprehensive review on metabolic syndromeReview of guidelines on primary prevention of cardiovascular disease with aspirin: how much evidence is needed to turn a tanker?Aspirin under fire: aspirin use in the primary prevention of coronary heart diseaseWomen's health study (aspirin) and TNTBalancing the gastrointestinal benefits and risks of nonselective NSAIDs.Aspirin and clopidogrel resistance: an emerging clinical entityNon-steroidal antiinflammatory drugs and the risk of acute myocardial infarctionCardioprotective aspirin users and their excess risk of upper gastrointestinal complicationsDose of aspirin in the treatment and prevention of cardiovascular disease: current and future directionsPlatelet activation in type 2 diabetes mellitusRisk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC studyIncidental cardiac findings on computed tomography imaging of the thorax.Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.Risk assessment and aspirin use in Asian and Western populations.Medical angioplasty - hope and expectations: an optimistic overview.Aspirin antagonism in isoniazid treatment of tuberculosis in miceAspirin use and cardiovascular events in social networks.Asymptomatic carotid stenosis: natural history and therapeutic implications.Associations between demographic, disease related, and treatment pathway related variables and health related quality of life in primary care patients with coronary heart disease.Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.An assessment of the joint associations of aspirin and statin use with C-reactive protein concentration.Essential fatty acids and their metabolites could function as endogenous HMG-CoA reductase and ACE enzyme inhibitors, anti-arrhythmic, anti-hypertensive, anti-atherosclerotic, anti-inflammatory, cytoprotective, and cardioprotective molecules.Peculiarities of stroke risk in women.Improving the gastrointestinal tolerability of aspirin in older people.Cardiovascular disease prevention tailored for women.Adaptive designs for randomized trials in public health.Low-dose aspirin and medical record-confirmed age-related macular degeneration in a randomized trial of women.Schisandra chinensis and Morus alba Synergistically Inhibit In Vivo Thrombus Formation and Platelet Aggregation by Impairing the Glycoprotein VI Pathway.Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran.Use of antiplatelet agents in patients with atherosclerotic disease.NF-κB signaling at the crossroads of inflammation and atherogenesis: searching for new therapeutic links.Adverse cardiac events associated with incident opioid drug use among older adults with COPD.Impact of wines and wine constituents on cyclooxygenase-1, cyclooxygenase-2, and 5-lipoxygenase catalytic activity.Effect of NSAIDs on Na⁺/H⁺ exchanger activity in rat colonic crypts.Antiplatelet therapy: present status and future prospects.Antiplatelet therapy: current strategies and future trends.The polypill and cardiovascular disease.Aspirin for the primary prevention of cardiovascular events: considerations regarding the risk/benefit.Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome.Inflammatory bowel disease is associated with an increased incidence of cardiovascular events.
P2860
Q21284500-321BC76E-CE08-4A1A-8CDE-C310F592ECADQ22241777-F19BA8BF-1B89-45FA-B81A-FCB657AEF8F7Q28176243-8396C167-2540-4FEC-8979-3E7807AA6DE9Q28184667-91E0AA87-893B-419E-AB7E-A85F83338B53Q28191932-218F7E6E-5081-460A-AE6C-135EBA4C84C1Q28194021-EC82038A-BCD1-4B3A-B257-EE6BFB2E1FE7Q28196509-88EC55F1-9023-4D10-9F21-120E831AEF0CQ28200511-989BF2F7-5FD1-47A3-9145-C3615E4EABBDQ28200895-E5023A91-DB73-4A0A-B9E9-FE4DE903CEE2Q28210554-1389AFE4-17E4-4B67-8E30-6F6C9C370E72Q33605890-7FCA7F28-07FB-4780-895D-A6E4B27F84BCQ33761879-D603AD2E-49F0-478A-BF18-B4328129D08AQ34007717-1ABEE068-1995-4BCA-BDA2-A3810A2C65ADQ34245212-EC34F835-1097-44B5-B375-23A6A2124082Q35610914-086F4E58-D9EF-457D-AE28-5A12794968BFQ35636044-44143CE9-6FA4-41D1-8CA8-2DDD2B1D1A99Q35818810-4322E851-1704-432B-959E-68D8C068DF2CQ36030440-02034343-8ED2-4740-BE76-A16C07992AE0Q36299388-251A5063-56E6-40BE-BBE4-BFB413BF6A03Q36438737-D4D6B504-82C3-4914-AF60-531BC87C0C38Q36851683-46C8753B-6D1A-45DE-9384-AE2D512A8DD4Q36957089-CB2C0B9E-8610-4B19-90C0-EB84998639FCQ36986385-59CB44AC-E5EB-4309-80D0-105D5184B444Q37019062-A7490D8D-13B8-4F58-9BEF-CB034EAAF264Q37269396-EAC5B2E2-FAFD-4F23-9097-0DFFC5087905Q37417713-508959B2-68AB-4711-8689-D86BDBEAF6F3Q37456134-0C28B516-C8E2-4518-B64C-0943CE526FC9Q37618371-65FCA251-6ED2-4A49-AFEC-395419E9D0A6Q37743623-D1371096-8D07-42CC-97AC-7637608A831CQ38151446-47DDE9B3-DACB-49A7-ACB1-530F696DFFEBQ38227386-0FCA6043-1F69-4738-B420-9BD56B4FF42FQ38701066-E8B3BC42-67AE-4C9D-A18D-08DE789DEA9EQ39153607-84090AD6-22E6-4FD7-8F2F-1FCEA4C3C7DAQ39226084-FF93E530-0176-4A8F-AB18-80EB13362535Q40188545-0650AEF3-6340-4545-A137-9300E3A5AB88Q40329892-F4FE7ADE-7F5C-4101-8437-68BBC9B3B225Q43045345-59F02E0E-2E59-4D5C-9F72-4567331972CCQ43083584-C7982B2E-A484-4F99-A918-3F5ECE3F1715Q43244897-76F17628-9E26-41E4-9B99-A480AA9326D9Q45002674-B0E151D8-F621-48A7-AA08-97873BF5BC1C
P2860
An update on aspirin in the primary prevention of cardiovascular disease
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
An update on aspirin in the primary prevention of cardiovascular disease
@ast
An update on aspirin in the primary prevention of cardiovascular disease
@en
An update on aspirin in the primary prevention of cardiovascular disease
@nl
type
label
An update on aspirin in the primary prevention of cardiovascular disease
@ast
An update on aspirin in the primary prevention of cardiovascular disease
@en
An update on aspirin in the primary prevention of cardiovascular disease
@nl
prefLabel
An update on aspirin in the primary prevention of cardiovascular disease
@ast
An update on aspirin in the primary prevention of cardiovascular disease
@en
An update on aspirin in the primary prevention of cardiovascular disease
@nl
P2093
P1476
An update on aspirin in the primary prevention of cardiovascular disease
@en
P2093
Charles H Hennekens
Patricia R Hebert
Rachel S Eidelman
Steven M Weisman
P304
P356
10.1001/ARCHINTE.163.17.2006
P407
P577
2003-09-22T00:00:00Z